Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Ramucirumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Cyramza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,033

    2019 Revenue in Millions : 925

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 1,033

    2020 Revenue in Millions : 1,033

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 971

    2021 Revenue in Millions : 1,033

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 975

    2022 Revenue in Millions : 971

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 973

    2023 Revenue in Millions : 975

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 76

    2014 Revenue in Millions : 384

    Growth (%) : 405%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 614

    2015 Revenue in Millions : 384

    Growth (%) : 60

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 758

    2016 Revenue in Millions : 614

    Growth (%) : 23

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 821

    2017 Revenue in Millions : 758

    Growth (%) : 8%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Cyramza

    Ramucirumab

    arrow
    ASCO GU
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    ASCO GU
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 925

    2018 Revenue in Millions : 821

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.